EndoChoice Holdings Inc. (NYSE:GI) Given Average Rating of “Hold” by Brokerages
Shares of EndoChoice Holdings Inc. (NYSE:GI) have been given a consensus broker rating score of 2.67 (Hold) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and one has issued a strong buy recommendation on the company. EndoChoice Holdings’ rating score has declined by 52.6% in the last three months as a result of a number of analysts’ ratings changes.
Brokers have set a 12 month consensus price objective of $8.50 for the company and are anticipating that the company will post ($0.53) earnings per share for the current quarter, according to Zacks. Zacks has also given EndoChoice Holdings an industry rank of 103 out of 265 based on the ratings given to related companies.
GI has been the topic of several recent analyst reports. Zacks Investment Research cut EndoChoice Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. JPMorgan Chase & Co. initiated coverage on EndoChoice Holdings in a research note on Wednesday, July 13th. They issued an “overweight” rating on the stock. William Blair cut EndoChoice Holdings from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Finally, Stifel Nicolaus cut their target price on EndoChoice Holdings from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, August 4th.
Shares of EndoChoice Holdings (NYSE:GI) traded up 2.09% during mid-day trading on Monday, hitting $4.39. The stock had a trading volume of 8,803 shares. The stock’s 50-day moving average price is $4.29 and its 200-day moving average price is $4.71. EndoChoice Holdings has a 52-week low of $3.64 and a 52-week high of $16.01. The firm’s market cap is $114.35 million.
EndoChoice Holdings (NYSE:GI) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.47. The company earned $19.30 million during the quarter, compared to analysts’ expectations of $20.67 million. EndoChoice Holdings had a negative return on equity of 62.04% and a negative net margin of 88.94%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.01) EPS. On average, analysts anticipate that EndoChoice Holdings will post ($2.53) earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of GI. State Street Corp boosted its stake in EndoChoice Holdings by 46.7% in the first quarter. State Street Corp now owns 76,915 shares of the company’s stock valued at $402,000 after buying an additional 24,500 shares during the last quarter. Wellington Management Group LLP boosted its stake in EndoChoice Holdings by 3.5% in the first quarter. Wellington Management Group LLP now owns 2,324,664 shares of the company’s stock valued at $12,111,000 after buying an additional 78,016 shares during the last quarter. Renaissance Technologies LLC boosted its stake in EndoChoice Holdings by 96.5% in the first quarter. Renaissance Technologies LLC now owns 114,606 shares of the company’s stock valued at $597,000 after buying an additional 56,297 shares during the last quarter. Iguana Healthcare Management LLC purchased a new stake in EndoChoice Holdings during the first quarter valued at $580,000. Finally, Emerald Acquisition Ltd. purchased a new stake in EndoChoice Holdings during the second quarter valued at $215,000. 37.71% of the stock is currently owned by institutional investors and hedge funds.
About EndoChoice Holdings
EndoChoice Holdings, Inc is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EndoChoice Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.